Lixin Pharmaceutical always attaches great importance to safe production, adheres to the policy of "safety first, prevention first, and comprehensive management", strictly abides by the "Safe Production Law of the People's Republic of China", and constantly improves the company's safety rules and regulations. In 2022, Lixin Pharmaceutical Shandong Factory Successfully passed the third-level standardization acceptance and obtained a certificate. In 2019, the Suzhou factory successfully passed the second-level standardization acceptance and obtained a certificate.
Lixin Pharmaceutical has continuously improved safety facilities, upgraded automation systems, and successfully completed the safety status evaluation report, HAZOP (Hazard and Operability) analysis report, LOPA analysis (including SIL rating) report, chemical reaction safety risk research and evaluation report, and occupational hazard control. Effect evaluation report, etc.